

Almirall reports net sales of 701.3 million euros, an increase of 2.4%

- The Dermatology area consolidates its growth with an increase of 12.4% compared to the same period in 2008
- Normalised net income in Q3 2009 is 127 million euros

Barcelona, 16 November 2009.- Almirall, the international pharmaceutical company headquartered in Spain, reports a sustained growth of net sales, which totalled 701.3 million euros at close of the third quarter, an increase of 2.4% compared to the previous year. This is due to stable sales in Spain, a figure of 401.4 million euros, and expansion from the affiliates and other partnership agreements at an international level, which represent 299.9 million euros.

Jorge Gallardo, Chairman and Chief Executive Officer states: *"Sustained growth by Almirall's sales up to the third quarter is a reflection of the progressive achievement of the objectives set within our corporate and commercial strategy, whereby the guidance announced for this year is to be maintained"*.

EBITDA in the first nine months of the year totals 210.3 million euros, down 3.3% due to a drop in Other Income versus 2008.

Almirall has achieved a normalised net income of 127 million euros at close of the third quarter of this year, a decrease of 5.2% compared to the same period of last year.

Up to the third quarter of 2009, Almirall allocated a total 81.5 million euros to R&D: 13.6% less than in the previous year due to lower expenditure in phase III trial carried out for Eklira[®] (aclidinium bromide), which were mostly booked in 2008.

Million of euros	YTD Sept. 2009	YTD Sept. 2008	% Variation
Net Sales	701,3	685,2	2,4%
Other Income	77,3	123,6	(37,5%)
R&D expenses	81,5	94,3	(13,6%)
EBITDA*	210,3	217,4	(3,3%)
Net income	140,7	132,6	6,1%
Normalized Net Income	127,0	134,0	(5,2%)

* EBITDA (earnings before interest, taxes, depreciations and amortizations)

Increasing of top 10 products

In the third quarter of 2009 the 10 highest selling products increased by 5.9% compared to the same period of the previous year. These 10 products now account for 450 million euros of the total 701.3 million euros net sales.

€million	YTD Sept 2009	YTD Sept 2008	variation
Ebastine	94,2	81,5	15,6%
Atorvastatin	89,6	77,6	15,3%
<i>Esertia</i> (escitalopram)	48,0	41,3	16,1%
<i>Plusvent</i> (salmeterol & fluticasone)	44,4	44,5	(0,3%)
Almotriptan	39,6	35,9	10,3%
Aceclofenac	32,7	38,4	(14,9%)
<i>Parapres</i> (candesartan cilexetile)	32,3	30,4	6,1%
<i>Opiren</i> (lansoprazole)	26,1	26,4	1,4%
<i>Dobupal</i> (venlafaxine)	26,0	36,8	(29,6%)
<i>Solaraze</i> (diclofenac sodium)	17,1	11,5	48,7%
Other	251,3	260,7	(3,6%)
Total	701,3	685,2	2,4%

In terms of therapeutic areas, Almirall's dermatology products continued to prove successful as this therapeutic area indicates a growth in sales of 12.4% compared to the third quarter of last year, exceeding 86 million euros in the current quarter.

Cardiovascular (142.7 million euros), central nervous system (126.8 million euros) and respiratory (146.3 million euros) specialities remain at the head of the sales ranking.

Almirall R&D

Almirall maintains its commitment to innovative medicines that present progress in pharmaceutical research and an opportunity for patients. With this in mind it allocated to R&D resources of 81.5 million euros during the first nine months of 2009.

One of the highlights of the **respiratory pipeline** is Eklira® (aclidinium bromide), an inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD). The company aim to file an application for marketing authorisation with the European Medicines Agency (EMA) in early 2010.

Almirall is also committed to the future of the **dermatology area**, and the company recently disclosed a new project for non-melanoma skin cancer, LAS41007, which is in phase II.

In the **auto-immune area**, Sativex® was earlier this year filed for registration for spasticity in multiple sclerosis. This compound is also in development (phase II) for oncological pain.

On 10 November the company announced it was investing 15 million US\$ in Ironwood's equity, according to the agreement signed between the companies in May this year and as a result of positive results obtained in two Phase III trials for chronic constipation for linaclotide. The compound is being developed for the treatment of irritable bowel syndrome with constipation and chronic constipation and will be commercialised exclusively by Almirall in all country members of the European Union plus Russia, CIS, Switzerland, Norway and Turkey, as well as other countries of the former Yugoslavia.

About Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatology indications.

Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.

For further information please visit the website at: www.almirall.com

More information:

Ketchum/SEIS

Sonia San Segundo/Victorino Ballesteros

sonia.sansegundo@ketchum.com

Tel.: 00 34 91 788 32 00